CAPE COD

Community-Acquired Pneumonia: Evaluation of COrticosteroiDs. and sub-trial CAPE COVID19 Community-Acquired Pneumonia: Evaluation of Corticosteroids in COronaVIrus Disease (CAPE COD)

This trial evaluated the effect of hydroxycortisone on survival or respiratory support among patients with critical COVID-19 

 

Primary objective: To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure 

 

Type of studyInterventionalRCT, Phase 3

 

Treatment testedHydroxycortisone

 

Countries: France

 

Number of sitesN/A 

 

Sample size290 

 

Study participants:  Adults, COVID-19 confirmed  by PCR or suspected (suggestive chest computed tomography scan result in the absence of any other cause of pneumoniaadmitted in ICU 

 

Study status Completed

 

Study documents

 

Principal investigator


More information

 

 

 

Last updated: September 2020

 

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.